These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Response to letter: "Does Ivabradine really limit dobutamine-induced tachycardia in stable heart failure patients: parallax in significance". Gallet R; Ternacle J; Lim P Int J Cardiol; 2015 Jan; 179():217. PubMed ID: 25464449 [No Abstract] [Full Text] [Related]
68. Ivabradine: a promising drug in cardiogenic shock to prevent the undesirable sinus tachycardia induced by dobutamine? Lattuca B; Roubille F Int J Cardiol; 2015 Jan; 178():308-10. PubMed ID: 25305680 [No Abstract] [Full Text] [Related]
69. Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps. Chang TI; Chertow GM J Am Coll Cardiol; 2011 Sep; 58(11):1162-4. PubMed ID: 21884955 [No Abstract] [Full Text] [Related]
70. Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials? Anker SD; McMurray JJ Eur Heart J; 2012 Nov; 33(22):2764-5. PubMed ID: 22927554 [No Abstract] [Full Text] [Related]
71. Electrocardiographic changes and beta-blocker toxicity. Long H; Howland MA; Hoffman RS Ann Emerg Med; 2003 Jul; 42(1):156-7; author reply 157. PubMed ID: 12852411 [No Abstract] [Full Text] [Related]
72. The prognostic value of heart rate at discharge in acute decompensation of heart failure with reduced ejection fraction. Bahouth F; Elias A; Ghersin I; Khoury E; Bar O; Sholy H; Khoury J; Azzam ZS ESC Heart Fail; 2022 Feb; 9(1):585-594. PubMed ID: 34821080 [TBL] [Abstract][Full Text] [Related]
74. 2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Wang CC; Wu CK; Tsai ML; Lee CM; Huang WC; Chou HH; Huang JL; Chi NH; Yen HW; Tzeng BH; Chang WT; Chang HY; Wang CH; Lu YY; Tsai JP; Su CH; Cherng WJ; Yin WH; Tsai CT; Wu YW; Lin JL; Hwang JJ Acta Cardiol Sin; 2019 May; 35(3):244-283. PubMed ID: 31249457 [TBL] [Abstract][Full Text] [Related]
75. Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study). Fu M; Ahrenmark U; Berglund S; Lindholm CJ; Lehto A; Broberg AM; Tasevska-Dinevska G; Wikstrom G; Ågard A; Andersson B; Clin Res Cardiol; 2017 Dec; 106(12):960-973. PubMed ID: 28795299 [TBL] [Abstract][Full Text] [Related]
76. Highlights of the year in JACC 2012. DeMaria AN; Bax JJ; Feld GK; Greenberg BH; Hall JL; Hlatky MA; Lew WY; Lima JA; Mahmud E; Maisel AS; Narayan SM; Nissen SE; Sahn DJ; Tsimikas S J Am Coll Cardiol; 2013 Jan; 61(3):357-85. PubMed ID: 23328613 [No Abstract] [Full Text] [Related]
77. It is all about heart rate. Or is it? Sarraf M; Francis GS J Am Coll Cardiol; 2012 May; 59(22):1946-7. PubMed ID: 22617189 [No Abstract] [Full Text] [Related]
78. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I; J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188 [TBL] [Abstract][Full Text] [Related]
79. Heart failure and COPD: time to SHIFT? Sanders-van Wijk S; van Empel V; Knackstedt C; Brunner-La Rocca HP Int J Cardiol; 2014 Mar; 172(2):293-4. PubMed ID: 24452222 [No Abstract] [Full Text] [Related]
80. [Ivabradine -- a novel approach for heart rate lowering]. Er F; Hoppe UC Dtsch Med Wochenschr; 2005 Jun; 130(24):1501-2. PubMed ID: 15942839 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]